UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 332

Sortiert nach

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Multiple sclerosis international, 2019-01, Vol.2019, p.7151685-19

2019

Link zum Volltext

Verfügbarkeit prüfen

The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling

Nature communications, 2021-09, Vol.12 (1), p.5263-5263, Article 5263

2021

Link zum Volltext

Verfügbarkeit prüfen

Casein Kinase 1α as a Regulator of Wnt-Driven Cancer

International journal of molecular sciences, 2020-08, Vol.21 (16), p.5940

2020

Link zum Volltext

Verfügbarkeit prüfen

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Lancet neurology, 2010-04, Vol.9 (4), p.381-390

2010

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Lancet neurology, 2011-04, Vol.10 (4), p.338-348

2011

Link zum Volltext

Verfügbarkeit prüfen

Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect

Annals of neurology, 2010-11, Vol.68 (5), p.693-702

2010

Link zum Volltext

Verfügbarkeit prüfen

A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth

Molecular cancer research, 2022-11, Vol.20 (11), p.1598-1610

2022

Link zum Volltext

Verfügbarkeit prüfen

Multiprotein GLI Transcriptional Complexes as Therapeutic Targets in Cancer

Life (Basel, Switzerland), 2022-11, Vol.12 (12), p.1967

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis

Multiple sclerosis, 2011-02, Vol.17 (2), p.181-191

2011

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in multiple sclerosis: effects of natalizumab

Annals of neurology, 2007-10, Vol.62 (4), p.335-346

2007

Link zum Volltext

Verfügbarkeit prüfen

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Neurology and therapy, 2024-04, Vol.13 (2), p.283-322

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

Annals of neurology, 2006-05, Vol.59 (5), p.780-787

2006

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Multiple sclerosis and related disorders, 2014-09, Vol.3 (5), p.607-619

2014

Link zum Volltext

Verfügbarkeit prüfen

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression

Neuro-oncology advances, 2022-01, Vol.4 (1), p.vdac144-vdac144

2022

Link zum Volltext

Verfügbarkeit prüfen

Noncanonical activation of GLI signaling in SOX2 + cells drives medulloblastoma relapse

Science advances, 2022-07, Vol.8 (29), p.eabj9138-eabj9138

2022

Link zum Volltext

Verfügbarkeit prüfen

Physical Activity Correlates With Neurological Impairment and Disability in Multiple Sclerosis

The journal of nervous and mental disease, 2008-06, Vol.196 (6), p.492-495

2008

Link zum Volltext

Verfügbarkeit prüfen

Engineering Rugged Field Assays to Detect Hazardous Chemicals Using Spore-Based Bacterial Biosensors

Methods in enzymology, 2017, Vol.589, p.51

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2021-09, Vol.20 (9), p.729-738

2021

Link zum Volltext

Verfügbarkeit prüfen

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

The New England journal of medicine, 2022-08, Vol.387 (8), p.704-714

2022

Link zum Volltext

Verfügbarkeit prüfen

Physical activity, self-efficacy, and health-related quality of life in persons with multiple sclerosis: analysis of associations between individual-level changes over one year

Quality of life research, 2013-03, Vol.22 (2), p.253-261

2013

Link zum Volltext

Verfügbarkeit prüfen

Detection of bacterial contamination in food matrices by integration of quorum sensing in a paper-strip test

Analyst (London), 2018-10, Vol.143 (19), p.4774-4782

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Annals of neurology, 2010-10, Vol.68 (4), p.494-502

2010

Link zum Volltext

Verfügbarkeit prüfen

Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids

CNS neuroscience & therapeutics, 2022-03, Vol.28 (3), p.364-371

2022

Link zum Volltext

Verfügbarkeit prüfen

Accelerometry in persons with multiple sclerosis: Measurement of physical activity or walking mobility?

Journal of the neurological sciences, 2010-03, Vol.290 (1), p.6-11

2010

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-06, Vol.256 (6), p.1035-1037

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 332

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(272)
Mit Volltextzugriff
(309)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(201)
Life Sciences & Biomedicine
(142)
Humans
(113)
Female
(86)
Male
(76)
Biological And Medical Sciences
(45)
Adult
(44)
Animals
(41)
Medical Sciences
(37)
Middle Aged
(37)
Neurosciences & Neurology
(36)
Clinical Neurology
(34)
Physical Sciences
(33)
Neurology
(28)
Multidisciplinary Sciences
(23)
Science & Technology - Other Topics
(23)
Multiple Sclerosis
(21)
Adolescent
(19)
Neurosciences
(19)
Treatment Outcome
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Science
(13)
Archaeologia Cambrensis
(12)
Blood
(8)
Contexts
(7)
Multiple Sclerosis
(7)
Annals Of Neurology
(6)
The Journal Of Immunology
(6)
International Journal Of Surgery
(5)
Lancet Neurology
(5)
Multiple Sclerosis And Related Disorders
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling

Casein Kinase 1α as a Regulator of Wnt-Driven Cancer

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect

A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth

Multiprotein GLI Transcriptional Complexes as Therapeutic Targets in Cancer

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis

Health-related quality of life in multiple sclerosis: effects of natalizumab

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression

Noncanonical activation of GLI signaling in SOX2 + cells drives medulloblastoma relapse

Physical Activity Correlates With Neurological Impairment and Disability in Multiple Sclerosis

Engineering Rugged Field Assays to Detect Hazardous Chemicals Using Spore-Based Bacterial Biosensors

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Physical activity, self-efficacy, and health-related quality of life in persons with multiple sclerosis: analysis of associations between individual-level changes over one year

Detection of bacterial contamination in food matrices by integration of quorum sensing in a paper-strip test

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids

Accelerometry in persons with multiple sclerosis: Measurement of physical activity or walking mobility?

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Suchergebnisse filtern